Strata Oncology Announces Poster Presentation at the American Society of Clinical Oncology (ASCO) Annual Meeting

May 4, 2021

Strata to present data on comprehensive genomic and transcriptomic profiling in patients
with advanced solid tumors

Strata Oncology, Inc., a precision oncology company advancing molecular indications for cancer therapies, today announced that its abstract on the use of comprehensive genomic and transcriptome profiling to predict the benefit of pembrolizumab in patients with advanced cancer was selected for poster presentation at the American Society of Clinical Oncology (ASCO) Annual Meeting, taking place virtually from June 4-8, 2021.

Details of the presentation are as follows:

Abstract title: Comprehensive genomic and transcriptomic profiling (CGTP) to predict pembrolizumab (P) benefit in patients (pts) with advanced solid tumors (STs)
Session title: Poster Session: Developmental Therapeutics—Immunotherapy

Additional meeting information is available on the ASCO website, where the abstract will be published on May 19, 2021.

Back to Newsroom Back to Newsroom

Media Inquiries

Rachel Ford Hutman rachel@fordhutmanmedia.com 301.801.5540

About Strata Oncology

Strata Oncology, Inc. is a precision oncology company dedicated to delivering the best possible treatment for each patient with cancer. The company combines molecular profiling, real-world data, and a large-scale clinical trial platform to identify and deliver optimal treatments for patients with cancer. For more information visit strataoncology.com.

About Us

In the news

The latest from Strata Oncology

December 1, 2023

Strata Oncology Announces Presentations on Proprietary Multivariate Biomarkers at North America Conference on Lung Cancer and San Antonio Breast Cancer Symposium

November 8, 2023

Strata Oncology Recognized as “Diagnostics Innovation Of The Year” by BioTech Breakthrough Awards

September 11, 2023

Dr. Nair on the clinical utility of Immunotherapy Response Score

September 10, 2023

Immunotherapy Response Score (IRS) Predicts Pembrolizumab Clinical Benefit in Patients with NSCLC in TPS≥50%

September 7, 2023

Strata Oncology Announces New Data Supporting Utility of Immunotherapy Response Score to Guide First-Line Treatment Decisions in Non-small Cell Lung Cancer

July 10, 2023

Immunotherapy Response Score (IRS) Predicts Pembrolizumab Clinical Benefit in Patients with NSCLC in TPS≥50%

July 3, 2023

Validation of Immunotherapy Response Score as predictive of pan-solid tumor anti-PD-1/PD-L1 benefit

June 14, 2023

Dr Thomas on the Predictive Value of IRS For Pembrolizumab Benefit in Advanced Solid Tumors

June 1, 2023

Evaluation of Immunotherapy Response Score (IRS) for Predicting Pembrolizumab (pembro) Clinical Benefit in Patients (pts) with Advanced Solid Tumors

May 2, 2023

Strata Oncology Receives Honorable Mention in Fast Company’s 2023 World Changing Ideas Awards